Ypsomed Holding AG (YPHDF)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Ypsomed Holding AG (YPHDF) trades at $430.00 with AI Score 50/100 (Grade B). Ypsomed Holding AG develops, manufactures, and sells injection and infusion systems for pharmaceutical and biotechnology companies, operating through its Delivery Systems and Diabetes Care segments. Market cap: $5.65B, Sector: Healthcare.
Price live · AI analysis from Jun 14, 2026Analyst Coverage for YPHDF: YPHDF does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates YPHDF against Healthcare peers across nine fundamental dimensions and assigns a mixed fundamental profile based on the underlying data.
YPHDF: the 1 perspectives are evenly split.
How is this calculated? →Ypsomed Holding AG (YPHDF) Healthcare & Pipeline Overview
Ypsomed Holding AG is a Swiss-based medical technology firm specializing in the development, manufacturing, and global distribution of advanced injection and infusion systems. Its dual focus on Ypsomed Delivery Systems for pharmaceutical partners and Ypsomed Diabetes Care for direct patient solutions positions it within the evolving healthcare device market, serving diverse therapeutic needs.
What Is the Investment Thesis for YPHDF?
Ypsomed Holding AG presents a compelling profile within the medical device sector, driven by its dual-segment strategy in drug delivery systems and diabetes care. The company's Ypsomed Delivery Systems segment benefits from the increasing demand for advanced, user-friendly injection solutions from pharmaceutical and biotechnology partners, positioning it to capitalize on the growing biologics market. Its YDS brand offers a range of innovative devices like pen, auto, patch, and wearable injectors, which are critical for enhancing patient adherence and therapeutic outcomes. Concurrently, the Ypsomed Diabetes Care segment, under the mylife brand, addresses a continuously expanding global diabetic population, providing essential tools such as insulin pumps and blood glucose monitoring systems. The company's financial metrics, including a P/E ratio of 17.33, a robust Profit Margin of 24.0%, and a Gross Margin of 42.3%, indicate efficient operations and profitability. A Beta of 0.74 suggests lower volatility compared to the broader market, potentially appealing to investors seeking stability. Future growth is anticipated through continued innovation in smart devices, expansion into new therapeutic areas for its delivery systems, and geographical market penetration, particularly in North America and emerging markets. Potential risks include intense competition, regulatory changes, and the inherent challenges of OTC market trading.
Based on FMP financials and quantitative analysis
YPHDF Key Highlights
- Market Capitalization of $5.65B, reflecting its significant presence in the medical device sector.
- Price-to-Earnings (P/E) ratio of 17.33, indicating market valuation relative to earnings.
- Profit Margin of 24.0%, demonstrating strong profitability from its operations.
- Gross Margin of 42.3%, highlighting efficient cost management in production.
- Beta of 0.74, suggesting lower volatility compared to the overall market.
Who Are YPHDF's Competitors?
YPHDF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| MSMKF MatsukiyoCocokara & Co. | $14.60 | +0.00% | $5.74B | 49 |
| SHTDF Sinopharm Group Co. Ltd. | $2.30 | +7.98% | $7.18B | 45 |
| SKHCF Sonic Healthcare Limited | $14.58 | +14.26% | $7.21B | — |
| TRSBF 3SBio Inc. | $2.15 | +0.00% | $5.38B | 52 |
| SSMXF Sysmex Corporation | $8.25 | -6.78% | $5.13B | 50 |
| DCTH Delcath Systems, Inc. | $13.61 | +3.11% | $469.84M | 73 |
| PYNKF Perimeter Medical Imaging AI, Inc. | $0.20 | +3.40% | $18.68M | 73 |
| SSII SS Innovations International, Inc. | $3.76 | -0.53% | $752.49M | 72 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are YPHDF's Key Strengths?
- Dual-segment business model providing diversification across B2B drug delivery and B2C diabetes care.
- Strong R&D capabilities leading to innovative injection and infusion systems.
- Established global distribution network and partnerships with pharmaceutical companies.
- High gross margin (42.3%) and profit margin (24.0%) indicating operational efficiency.
What Are YPHDF's Weaknesses?
- Reliance on pharmaceutical partners for its Delivery Systems segment, subject to their R&D cycles and market success.
- Exposure to intense competition in both drug delivery and diabetes care markets.
- Potential challenges associated with trading on the OTC market, including lower liquidity and disclosure.
- Unknown disclosure status on the OTC market could deter some institutional investors.
What Could Drive YPHDF Stock Higher?
- Potential new partnerships with pharmaceutical and biotechnology companies for its YDS delivery systems, driving adoption of new injectable therapies.
- Continued innovation and launch of new smart and connected devices within both the Ypsomed Delivery Systems and Ypsomed Diabetes Care segments, enhancing product portfolio and market differentiation.
- Expansion into new geographic markets, particularly in North America, through enhanced distribution channels or strategic alliances, increasing market reach and sales volumes.
- Growth in the global diabetes care market, fueled by increasing prevalence rates, sustaining demand for mylife insulin pumps and monitoring systems.
- Successful clinical trials and regulatory approvals for new drugs utilizing Ypsomed's delivery systems by its pharmaceutical partners, translating into increased device sales.
What Are the Key Risks for YPHDF?
- Intense competition in both the drug delivery device and diabetes care markets from established global players and emerging innovators.
- Regulatory changes or delays in product approvals in key markets, impacting market entry or product updates.
- Dependence on the R&D success and market adoption of pharmaceutical partners' drugs for the growth of its Delivery Systems segment.
- Currency exchange rate fluctuations, given its international operations and Swiss headquarters, which could impact reported earnings.
- Challenges associated with trading on the OTC market, including lower liquidity and potential difficulties in price discovery.
What Are the Growth Opportunities for YPHDF?
- Expansion into New Therapeutic Areas for Delivery Systems: Ypsomed's YDS segment, which develops pen, auto, patch, and wearable injectors, is well-positioned to expand its application beyond current uses. As pharmaceutical and biotechnology companies develop new injectable drugs for conditions such as autoimmune diseases, oncology, and rare diseases, Ypsomed can adapt its existing platform technologies or innovate new ones to meet these specific therapeutic requirements. The global market for injectable drug delivery devices is projected to continue its robust growth, driven by the increasing pipeline of biologics and biosimilars. By securing new partnerships with pharmaceutical companies for these emerging therapies, Ypsomed can tap into substantial new revenue streams, leveraging its established reputation for precision and reliability in drug delivery.
- Geographic Market Penetration, particularly North America: While Ypsomed already operates internationally, there remains significant opportunity for deeper market penetration, especially in high-value regions like North America. The US market, in particular, represents a substantial portion of global healthcare spending and medical device consumption. Expanding its direct sales and distribution networks, or forming strategic alliances with local partners, could significantly increase the adoption of both its YDS products and mylife diabetes care solutions. This expansion would allow Ypsomed to capture a larger share of these mature and growing markets, capitalizing on the high demand for advanced medical devices and diabetes management tools.
- Innovation in Smart and Connected Drug Delivery Devices: The trend towards digital health and connected medical devices presents a significant growth avenue. Ypsomed's development of "smart devices" within its YDS segment indicates a strategic focus on this area. Further integrating connectivity, data analytics, and user-friendly interfaces into its injectors and diabetes care products (e.g., smart insulin pumps that communicate with continuous glucose monitors) can enhance patient adherence, improve treatment outcomes, and provide valuable data for healthcare providers. This innovation can differentiate Ypsomed from competitors, command premium pricing, and create new service-based revenue models, tapping into the rapidly expanding digital therapeutics market.
- Growth in Contract Manufacturing and Precision Turned Parts: Beyond its branded products, Ypsomed offers contract manufacturing and precision turned parts services. As pharmaceutical and medical device companies increasingly outsource specialized manufacturing to focus on core competencies, Ypsomed's expertise in high-precision components and complex assembly processes becomes a valuable asset. This segment can be expanded by actively seeking new contract manufacturing agreements, leveraging its state-of-the-art facilities and quality control systems. This diversification provides a stable revenue stream, reduces reliance on proprietary product cycles, and allows the company to capitalize on broader industrial trends requiring high-tolerance manufacturing.
- Strategic Partnerships and Acquisitions for Portfolio Expansion: To accelerate growth and expand market reach, Ypsomed could pursue strategic partnerships or targeted acquisitions. Collaborating with technology firms to integrate advanced sensors or AI into its devices, or acquiring smaller innovative companies with complementary product lines (e.g., non-invasive glucose monitoring technologies, advanced infusion therapies), could significantly enhance its competitive position. Such strategies would allow Ypsomed to quickly enter new market segments, acquire proprietary technologies, or gain access to new customer bases, thereby strengthening its overall product portfolio and market share in the rapidly evolving medical device landscape.
What Opportunities Does YPHDF Have?
- Growing global prevalence of chronic diseases, particularly diabetes, driving demand for its products.
- Increasing adoption of self-administration devices and connected health solutions.
- Expansion into new geographic markets, especially high-growth regions.
- Strategic partnerships or acquisitions to broaden product portfolio and technological capabilities.
What Threats Does YPHDF Face?
- Regulatory changes and evolving compliance requirements in the medical device industry.
- Intensifying competition from both established players and new entrants.
- Technological obsolescence if innovation pace slows relative to market demands.
- Supply chain disruptions or raw material price volatility impacting manufacturing costs.
What Are YPHDF's Competitive Advantages?
- Specialized expertise and intellectual property in developing complex, user-friendly injection and infusion systems.
- Established relationships with pharmaceutical and biotechnology partners for its YDS segment.
- Dual-segment strategy providing diversification across B2B drug delivery and B2C diabetes care markets.
- Global distribution network and established brand recognition (mylife) in diabetes management.
- High-quality manufacturing capabilities for precision components and contract services.
What Does YPHDF Do?
Founded in 1984 and headquartered in Burgdorf, Switzerland, Ypsomed Holding AG has evolved into a significant player in the medical technology sector, focusing on innovative drug delivery and diabetes care solutions. The company's operations are strategically divided into two primary segments: Ypsomed Delivery Systems and Ypsomed Diabetes Care. The Ypsomed Delivery Systems segment is dedicated to partnering with pharmaceutical and biotechnology companies, providing a comprehensive suite of advanced injection systems. This includes sophisticated pen injectors, auto injectors designed for ease of use, cutting-edge patch injectors, and wearable injectors, alongside other smart devices aimed at improving drug administration. These products, offered under the YDS brand, are crucial for facilitating the precise and convenient delivery of various medications, addressing a critical need for pharmaceutical partners seeking reliable and user-friendly solutions for their drug portfolios. The Ypsomed Diabetes Care segment, operating under the mylife brand name, focuses directly on enhancing the lives of individuals with diabetes. This segment is involved in the sale and trade of essential diabetes management tools, including advanced insulin pumps, a variety of infusion sets, high-quality pen needles, and comprehensive blood glucose monitoring systems. Additionally, it provides a range of accessories and other day-to-day items vital for effective diabetes self-management. Beyond its core product segments, Ypsomed Holding AG also leverages its manufacturing expertise to offer precision turned parts and provides contract manufacturing and other services, demonstrating its versatile capabilities. The company employs a multi-channel market approach, distributing its products through strategic biotechnology and pharmaceutical partners, as well as through its own established distribution network and independent distributors. With a robust international presence, Ypsomed operates across key regions including Switzerland, Europe, North America, and other global markets, underscoring its commitment to serving a broad patient and industry base worldwide. Its long-standing history since 1984 reflects a sustained commitment to innovation and quality in the medical device industry.
What Products and Services Does YPHDF Offer?
- Develops and manufactures advanced injection systems like pen, auto, patch, and wearable injectors for pharmaceutical companies.
- Sells insulin pumps, infusion sets, and pen needles for individuals managing diabetes.
- Provides blood glucose monitoring systems and related accessories under the mylife brand.
- Offers precision turned parts for various industrial and medical applications.
- Engages in contract manufacturing services for other companies in the healthcare sector.
- Distributes its products globally through partners, its own network, and independent distributors.
- Operates in two main segments: Ypsomed Delivery Systems (YDS) and Ypsomed Diabetes Care.
How Does YPHDF Make Money?
- Generates revenue from the sale of proprietary injection and infusion systems to pharmaceutical and biotechnology partners (Ypsomed Delivery Systems segment).
- Earns income from the direct sale and trade of diabetes care products, including insulin pumps, consumables, and monitoring systems, to patients and healthcare providers (Ypsomed Diabetes Care segment).
- Provides contract manufacturing services and sells precision turned parts to external clients, leveraging its manufacturing capabilities.
- Utilizes a global distribution network, including direct sales, partnerships, and independent distributors, to reach diverse markets.
What Industry Does YPHDF Operate In?
Ypsomed Holding AG operates within the dynamic and growing Medical Devices industry, a critical component of the broader Healthcare sector. The company's strategic focus on drug delivery systems and diabetes care places it at the intersection of several key market trends, including the rising prevalence of chronic diseases like diabetes, the increasing adoption of self-administration devices, and the growing pipeline of injectable biologics. The global market for drug delivery devices is expanding due to advancements in biotechnology and a preference for less invasive treatment methods. Similarly, the diabetes care market continues to grow, driven by an aging population and increasing diabetes incidence worldwide. Ypsomed's competitive landscape includes specialized medical device manufacturers and larger diversified healthcare companies. Its differentiation stems from its dual expertise in both B2B pharmaceutical partnerships (YDS) and direct-to-patient diabetes solutions (mylife), allowing it to capture value across different segments of the healthcare ecosystem. The company navigates this environment through continuous innovation and strategic partnerships, aiming to maintain its market position against established and emerging competitors.
Who Are YPHDF's Key Customers?
- Pharmaceutical and biotechnology companies requiring advanced drug delivery systems for their injectable medications.
- Individuals with diabetes who need insulin pumps, blood glucose monitors, and associated consumables for daily management.
- Healthcare providers and clinics that recommend or prescribe Ypsomed's diabetes care products.
- Industrial clients seeking high-precision turned parts and specialized contract manufacturing services.
ROE 29%Key Financial Metrics
Return on equity for Ypsomed Holding AG stands at 28.5%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 16.5%, showing how much profit it generates from its asset base. YPHDF trades at a trailing price-to-earnings ratio of 21.93, roughly in line with the Healthcare sector average of ~23x. Its free cash flow yield is 0.2%, a gauge of the cash the business throws off relative to its market value. A current ratio of 1.07 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is 4.6%, the inverse of the P/E and a quick read on earnings relative to price.
Ypsomed Holding AG (YPHDF) Valuation Context
Valued at $5.65B, YPHDF is classified as a mid-cap stock. Relative to its peer group, YPHDF's quantitative score of 50/100 is roughly in line with the peer average of 49/100.
Company Profile
Ypsomed Holding AG operates in the Medical - Devices industry within the Healthcare sector. It is headquartered in Burgdorf, CH. The company is led by CEO Simon Michel. YPHDF has traded publicly since 2022.
F-Score 8/9Financial Health
Ypsomed Holding AG's Piotroski F-Score is 8/9, a 9-point checklist of profitability, leverage and efficiency — signaling solid underlying fundamentals. Its Altman Z-Score of 7.13 places it in the safe zone, indicating low near-term bankruptcy risk.
FY2026 estForward Outlook
Wall Street analysts project Ypsomed Holding AG revenue of about $901.5M for fiscal 2026, with EPS near $16.67. The estimate reflects 10 contributing analysts.
YPHDF Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2026
Bull Case vs Bear Case
Bull Case
- Ypsomed has seen increased insider buying recently, indicating confidence from leadership in the company's future performance.
- Community sentiment has shifted positively, with discussions highlighting Ypsomed's innovative products in the diabetes management sector.
- Recent partnerships with healthcare providers have bolstered Ypsomed's market position, enhancing its reputation in the industry.
- The growing demand for diabetes care solutions aligns well with Ypsomed's strategic focus, appealing to health-conscious investors.
Bear Case
- Concerns over regulatory changes in the healthcare sector have led to some bearish sentiment among investors.
- Recent social media discussions reveal skepticism about Ypsomed's ability to maintain its growth momentum amid increasing competition.
- Some analysts have pointed out potential supply chain issues that could impact Ypsomed's production capabilities.
- The overall market volatility has created a cautious atmosphere, leading some investors to reevaluate their positions in healthcare stocks.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
YPHDF Latest News
No recent news available for YPHDF.
YPHDF Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for YPHDF.
Price Targets
Wall Street price target analysis for YPHDF.
YPHDF MoonshotScore
What does this score mean?
The MoonshotScore rates YPHDF's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Simon Michel
CEO
Simon Michel serves as the CEO of Ypsomed Holding AG, a role in which he oversees the strategic direction and operational execution for the company's 2600 employees. His leadership is critical in navigating the complex medical technology landscape, driving innovation in drug delivery systems and diabetes care. While specific details on his educational background and prior roles are not provided in the source data, his position as CEO of a publicly traded medical device company suggests a strong foundation in business management, healthcare, or engineering, coupled with extensive leadership experience within the sector.
Track Record: Under Simon Michel's leadership, Ypsomed Holding AG has maintained its dual-segment focus, successfully developing and marketing advanced injection and infusion systems for pharmaceutical partners and comprehensive diabetes care solutions. His tenure has seen the company sustain strong financial performance, evidenced by a 24.0% profit margin and 42.3% gross margin. He has been instrumental in managing the company's global operations and fostering innovation in smart device technologies, ensuring Ypsomed's continued relevance in a competitive market.
YPHDF OTC Market Information
Ypsomed Holding AG trades on the OTC market under the "OTC Other" tier. This classification signifies that the company does not meet the requirements for OTCQX or OTCQB, which are higher tiers with more stringent financial reporting and disclosure standards. Companies in the "OTC Other" tier typically have limited public disclosure, which can make it challenging for investors to access comprehensive and timely financial information compared to companies listed on major exchanges like NYSE or NASDAQ. This tier often includes international companies that do not wish to meet U.S. exchange listing requirements, or those with less robust reporting.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited transparency due to unknown disclosure status, making comprehensive financial analysis difficult.
- Lower liquidity and wider bid-ask spreads, potentially leading to higher transaction costs and difficulty in exiting positions.
- Increased price volatility due to lower trading volumes and fewer market makers.
- Reduced regulatory oversight compared to major exchanges, offering less investor protection.
- Difficulty in obtaining reliable, real-time market data and news.
- Verify the company's latest available financial statements directly from their corporate website or official Swiss regulatory filings.
- Research any news or press releases issued by the company itself, rather than relying solely on OTC market aggregators.
- Assess the company's business fundamentals, including market position, product pipeline, and competitive landscape, independently.
- Understand the specific risks associated with investing in a foreign company traded on the OTC market, including currency fluctuations and international regulatory differences.
- Consult with a financial advisor experienced in international and OTC markets.
- Evaluate the company's investor relations efforts and accessibility of information.
- Examine the historical trading volume and price action to gauge liquidity and volatility.
- Established founding date in 1984, indicating a long operational history.
- Headquartered in Burgdorf, Switzerland, suggesting a regulated home market.
- Clear business description with specific products (e.g., mylife brand) and operational segments.
- Significant employee count of 2600, indicating a substantial operating entity.
- Reported market capitalization of $5.65B, suggesting a sizable company despite OTC listing.
What Investors Ask About Ypsomed Holding AG (YPHDF) — Healthcare
What are the key growth opportunities for YPHDF in healthcare?
Ypsomed Holding AG has several key growth opportunities within the healthcare sector. One significant avenue is the expansion of its Ypsomed Delivery Systems segment into new therapeutic areas. As pharmaceutical companies develop more injectable biologics for conditions like autoimmune diseases, oncology, and rare disorders, Ypsomed can adapt its advanced pen, auto, patch, and wearable injectors to serve these growing markets, securing new partnerships. Another opportunity lies in deeper geographic penetration, particularly in high-value markets such as North America, where demand for advanced medical devices is robust. Furthermore, continuous innovation in smart and connected drug delivery devices, integrating digital health solutions, can differentiate its offerings and create new revenue streams, aligning with the broader trend towards personalized and data-driven healthcare.
How does Ypsomed Holding AG differentiate its products in the competitive medical device market?
Ypsomed Holding AG differentiates its products through a combination of specialized expertise, a dual-segment strategy, and a focus on user-friendly innovation. In its Ypsomed Delivery Systems segment, the company offers a comprehensive portfolio of precision-engineered injectors (pen, auto, patch, wearable) that are critical for pharmaceutical partners seeking reliable and easy-to-use solutions for complex drugs. This B2B focus on advanced technology sets it apart. Concurrently, its Ypsomed Diabetes Care segment, under the mylife brand, provides integrated solutions like insulin pumps and monitoring systems designed for patient convenience and improved adherence. This direct-to-patient approach, coupled with a commitment to quality and smart device integration, helps Ypsomed stand out in a crowded market by addressing both industry and patient needs effectively.
What are the implications of YPHDF trading on the OTC market for investors?
YPHDF's trading on the OTC market, specifically in the "OTC Other" tier with an "Unknown" disclosure status, carries several implications for investors. Primarily, it suggests potentially lower liquidity compared to stocks on major exchanges, which can lead to wider bid-ask spreads and greater difficulty in executing trades at desired prices. The "Unknown" disclosure status means investors may face challenges in accessing comprehensive and timely financial reports, making thorough due diligence more complex. Additionally, OTC markets generally have less stringent regulatory oversight, which could translate to fewer investor protections. Investors should be prepared for potentially higher volatility and the need for more independent research, directly consulting the company's official corporate communications and Swiss regulatory filings for information.
What are the key factors to evaluate for YPHDF?
Ypsomed Holding AG (YPHDF) holds an AI score of 50/100 (moderate). Not financial advice.
How frequently does YPHDF data refresh on this page?
YPHDF prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven YPHDF's recent stock price performance?
Ypsomed Holding AG (YPHDF) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Dual-segment business model providing diversification across B2B drug delivery and B2C diabetes care. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider YPHDF overvalued or undervalued right now?
Valuing Ypsomed Holding AG (YPHDF) requires multiple metrics. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying YPHDF?
Before investing in Ypsomed Holding AG (YPHDF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- CEO tenure years not provided in source data.
- Specific educational background and prior roles for CEO not provided in source data.
- Analyst consensus/ratings not provided, so FAQ adjusted to company fundamentals.